ROMA, an algorithm for ovarian cancer

Clinica Chimica Acta

Volumn 440, Issue , 2015, Pages 143-151

  Chudecka Głaz, Anita Monika ^a  

^a POMERANIAN MEDICAL UNIVERSITY   (Poland)

Author keywords

CA 125; HE4; Ovarian cancer; ROMA

Indexed keywords

CA 125 ANTIGEN; HUMAN EPIDIDYMIS PROTEIN 4; MEMBRANE PROTEIN; MUC16 PROTEIN, HUMAN; PROTEIN; WFDC2 PROTEIN, HUMAN;

ALGORITHM; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER MORTALITY; CANCER RISK; CLINICAL TRIAL (TOPIC); DIAGNOSTIC ACCURACY; DIAGNOSTIC KIT; HUMAN; OVARY CANCER; POSTMENOPAUSE; PREDICTIVE VALUE; PREMENOPAUSE; REPRODUCIBILITY; REVIEW; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; BLOOD; COMPUTER ASSISTED DIAGNOSIS; ECHOGRAPHY; FEMALE; OVARIAN NEOPLASMS; PROCEDURES;

ALGORITHMS; CA-125 ANTIGEN; CLINICAL TRIALS AS TOPIC; DIAGNOSIS, COMPUTER-ASSISTED; FEMALE; HUMANS; MEMBRANE PROTEINS; OVARIAN NEOPLASMS; PROTEINS; SENSITIVITY AND SPECIFICITY;

EID: 84912101570     PISSN: 00098981     EISSN: 18733492     Source Type: Journal    
DOI: 10.1016/j.cca.2014.11.015     Document Type: Review

References (123)

1. Ferlay J., Soerjomataram I., Ervik M., et al. Globocan 2012 v 1.0, Cancer Incidence and Mortality Worldwide: IARC Cancer Base No . 11 2013, International Agency for Research on Cancer, Lyon, France, [Available from: http://globcan.iarc.fr, accessed on 20 JUL 2014].
2. De Angelis R., Sant M., Coleman M.P., et al. Cancer survival in Europe 1999-2007 by country and age: results of EUROCARE-5 a population based study. Lancet Oncol 2014, 15:23-34.
3. Koshiyana M., Matsumura N., Konishi I. Recent concepts of ovarian carcinogenesis: type I and type II. BioMed Res Int 2014, 2014:934261.
4. Jacobs I., Oram D., Fairbanks J., Turner J., Frost C., Grudzinskas J.G. A risk of malignancy index incorporating CA 125, ultrasound and menopausal status for the accurate preoperative diagnosis of ovarian cancer. Br J Obstet Gynecol 1990, 97:922-929.
5. Macuks R., Baidekalna I., Donina S. Comparison of different ovarian cancer detection algorithms. Eur J Gynaecol Oncol 2011, 32:408-410.
6. Moore R.G., McMeekin D.S., Brown A.K., et al. A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass. Gynecol Oncol 2009, 112:40-46.
7. Moore R.G., Miller M.C., Disilvestro P., et al. Evaluation of the diagnostic accuracy of the risk of ovarian malignancy algorithm in women with a pelvic mass. Obstet Gynecol 2011, 118:280-288.
8. Macus R., Baidekalna I., Donina S. An ovarian cancer malignancy risk index composed of HE4, CA 125, ultrasonographic score, and menopausal status: use in differentiation of ovarian cancers and benign lesions. Tumor Biol 2012, 33:1811-1817.
9. Kaijser J., Van Gorp T., Hoorde K.V., et al. A comparison between an ultrasound based prediction model (LR2) and the risk of ovarian malignancy algorithm (ROMA) to assess the risk of malignancy in women with adnexal mass. Gynecol Oncol 2013, 129:377-383.
10. Ferraro S., Braga F., Lanzoni M., Boracchi P., Biganzoli E.M., Panteghini M. Serum human epididymis protein 4 vs carbohydrate antigen CA 125 for ovarian cancer diagnosis. J Clin Pathol 2013, 66:273-281.
11. Kaijser J., Van Gorp T., Smet M.E., et al. Are serum HE4 or ROMA scores useful to experienced examiners for improving characterization of adnexal masses after transvaginal ultrasonography?. Ultrasound Obstet Gynecol 2014, 43:89-97.
12. Kijser J. Differentiating stage I epithelial ovarian cancer from benign disease in women with adnexal tumor s using biomarkers or the ROMA algorithm. Gynecol Oncol 2013, 130:398-400.
13. Pitta D., Sarian L.O., Barreta A., et al. Symptoms, CA 125 and HE4 for the preoperative prediction of ovarian malignancy in Brazilian women with ovarian masses. BMC Cancer 2013, 13:423.
14. Escudero J.M., Auge J.M., Filella X., Torne A., Pahisa J., Molina R. Comparison of serum human epididymis protein 4 with cancer antigen 125 as tumor marker in patients with malignant and non-malignant disease. Clin Chem 2011, 57:1534-1544.
15. Havrilesky L.J., Whitehead C.M., Rubatt J.M., et al. Evaluation of biomarker panels for early stage ovarian cancer detection and monitoring for disease recurrence. Gynecol Oncol 2008, 110:374-382.
16. Yurkovetsky Z., Skates S., Lomakin A., et al. Development of a multimarker assay for early detection of ovarian cancer. J Clin Oncol 2010, 28:2159-2166.
17. Anton C., Carvalho F.M., Oliveira E.I., Maciel G.A.R., Baracat C.B., Carvalho J.P. A comparison of CA125, HE4, risk ovarian malignancy algorithm (ROMA), and risk malignancy index (RMI) for the classification of ovarian masses. Clinics 2012, 67:437-441.
18. Reade C., Riva J., Busse J.W., Goldsmith C., Elit L. Risk and benefits of screening women for ovarian cancer: a systematic review and meta-analysis. Gynecol Oncol 2013, 130:674-681.
19. Van Gorp T., Veldman J., Van Calster B., et al. Subjective assessment by ultrasound is superior to the risk of malignancy index (RMI) or the risk of ovarian malignancy algorithm (ROMA) in discriminating benign from malignant adnexal masses. Eur J Cancer 2012, 48:1649-1656.
20. Rein B.J., Gupta S., Dada R., Safi J., Michener C., Agarwal A. Potential markers for detection and monitoring of ovarian cancer. J Oncol 2011, 2011:475983.
21. Bast R.C., Brewer M., Zou C., et al. Prevention and early detection of ovarian cancer: mission impossible?. Recent Results Cancer Res 2007, 174:91-100.
22. Bast R.C., Skates S., Lokshin A., Moore R.G. Differential diagnosis of a pelvic mass: improved algorithms and novel biomarkers. Int J Gynecol Cancer 2012, 22(Suppl.):S5-S8.
23. Leung F., Diamandis E.P., Kulasingam V. From bench to bedside: discovery of ovarian cancer biomarkers using high-throughput technologies in the past decade. Biomark Med 2012, 6:613-625.
24. Plebani M. HE4 in gynecological cancers: report of a European investigators and experts. Clin Chem Lab Med 2012, 50:2127-2136.
25. Plebani M., Melichar B. ROMA or death: advances in epithelial ovarian cancer diagnosis. Clin Chem Lab Med 2011, 49:433-435.
26. Morgante G., Ia Marca A., Ditto A., De Leo V. Comparison of two malignancy risk indices based on serum Ca125, ultrasound score and menopausal status in the diagnosis of ovarian masses. Br J Obstet Gynaecol 1999, 106:524-527.
27. Tinglustad S., Hagen B., Skjeldestad F.E., Halvorsen T., Nustad K., Onsrud M. The risk of malignancy index to evaluate potential ovarian cancers in local hospitals. Obstet Gynecol 1999, 93:448-452.
28. Zhang Z., Chan D.W. The road from discovery to clinical diagnostics: lessons learned from the first FDA-cleared in vitro diagnostic multivariate index assay of proteomic biomarkers. Cancer Epidemiol Biomarkers Prev 2010, 19:2995-2999.
29. Ware Miller R., Smith A., Desimone C.P., et al. Performance of the American Collage of Obstetricians and Gynecologists' ovarian tumor referral guidelines with multivariate index assay. Obstet Gynecol 2011, 117:1298-1306.
30. Ueland F.R., Desimone C.P., Seamon L.G., et al. Effectiveness of multivariate index assay in the preoperative assessment of ovarian tumors. Obstet Gynecol 2011, 117:1289-1297.
31. Bast R.C., Feeney M., Lazarus H., Nadler L.M., Colvin R.B., Knapp R.C. Reactivity of a monoclonal antibody with human ovarian carcinoma. J Clin Invest 1981, 68:1331-1337.
32. Bast R.C., Klug T.L., St John E., et al. A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med 1983, 309:169-171.
33. Tholander B., Taube A., Lindgren A., Sjöberg O., Stendahl U., Tamsen L. Pretreatment serum levels of CA-125, carcinoembryonic antigen, tissue polypeptide antigen, and placental alkaline phosphatase in patients with ovarian carcinoma: influence of histological type, grade of differentiation, and clinical stage of disease. Gynecol Oncol 1990, 39:26-33.
34. Ruibal A., Encabo G., Martinez-Mirales E., et al. CA 125 seric levels in non-malignant pathologies. Bull Cancer 1984, 71:145-146.
35. Niloff J.M., Klug T.L., Schaetzl E., Zurawski V.R., Knapp R.C., Bast R.C. Elevation of serum CA 25 in carcinomas of fallopian tube, endometrium, and endocervix. Am J Obstet Gynecol 1984, 148:1057-1058.
36. Jacobs B.I., Bast R.C. The CA 125 tumor-associated antigen: a review of the literature. Hum Reprod 1989, 4:1-12.
37. Lutz A.M., Willmann J.K., Drescher C.W., et al. Early diagnosis of ovarian carcinoma: is a solution in sight?. Radiology 2011, 259:329-345.
38. Duffy M.J., Bonfer J.M., Kulpa J., et al. CA 125 in ovarian cancer: European Group on Tumor Markers guidelines for clinical use. Int J Gynecol Cancer 2005, 15:679-691.
39. Bast R.C. Status of tumor markers in ovarian cancer screening. J Clin Oncol 2003, 21:200s-205s.
40. Rustin G.J., Vergote I., Eisenhauer E., et al. Definitions for response and progression in ovarian cancer clinical trials incoroporatingg RECIST 1.1 and CA 125 agreed by the Gynecologic Cancer Intergroup (GCIG). Int J Gynecol Cancer 2011, 21:419-423.
41. Yedema C.A., Kenemans P., Wobbes T., et al. Use of serum tumor markers in the differentia diagnosis between ovarian and colorectal carcinomas. Tumor Biol 1992, 13:18-26.
42. Sorensen S.S., Mosgaard B.J. Combination of cancer antigen CA125 and carcinoembryonic antigen can improve ovarian cancer diagnosis. Dan Med Bull 2011, 58:A4331.
43. Makar A.P., Kristensen G.B., Kaern J., Bormer O.P., Abeler V.M., Trope C.G. Prognostic value of pre- and postoperative serum CA 125 levels in ovarian cancer: new aspects and multivariate analysis. Obstet Gynecol 1992, 79:1002-1010.
44. Parker D., Bradley C., Bogle S.M., et al. Serum albumin and CA 125 are powerful predictors of survival in epithelial ovarian cancer. Br J Obstet Gynaecol 1994, 101:888-893.
45. Bandiera E., Romani C., Specchla C., et al. Serum human epididymis protein 4 and risk for ovarian malignancy algorithm as new diagnostic and prognostic tools for epithelial ovarian management. Cancer Epidemiol Biomarkers Prev 2011, 20:2496-2506.
46. Ławicki S., Bdkowska E.G., Gacuta-Szumarska E., Szmitkowski M. The plasma concentration of VEGF, HE4 and CA 125 as new biomarkers panel in different stages and subtypes of epithelial ovarian tumors. J Ovarian Res 2013, 6:45.
47. Hellström I., Raycraft J., Hayden-Ledbetter M., et al. The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma. Cancer Res 2003, 63:3695-3700.
48. Hellstrom I., Hellstrom K.E. Two novel biomarkers, mesothelin and HE4, for diagnosis of ovarian carcinoma. Exp Opin Med Diagn 2011, 5:227-240.
49. Drapkin R., von Horsten H.H., Lin Y., et al. Human epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas. Cancer Res 2005, 65:2162-2169.
50. Kadija S., Stefanovic A., Jeremic K., et al. The utility of human epididymal protein 4, cancer antigen 125, and risk form malignancy algorithm in ovarian cancer and endometriosis. Int J Gynecol Cancer 2012, 22:238-244.
51. Langmár Z., Németh M., Vleskó G., Király M., Hornyák L., Bosze P. HE4- a novel promising serum marker in the diagnosis of ovarian carcinoma. Eur J Gynaecol Oncol 2011, 32:605-610.
52. Kirchoff C., Habben I., Ivell R., Krull N. A major human epididymis - specific cDNA encodes a protein with sequence homology to extracellular proteinase inhibitors. Biol Reprod 1991, 45:350-357.
53. Kirchoff C. Molecular characterization of epididymal proteins. Rev Reprod 1998, 3:86-95.
54. Lu R., Sun X., Xiao R., Zhou L., Gao X., Guo L. Human epididymis protein 4 (HE4) plays a key role in ovarian cancer cell adhesion and motility. Biochem Biophys Res Commun 2012, 419:274-280.
55. Zou S., Chang X., Ye X., et al. Effect of human epididymis protein 4 gene silencing on the malignant phenotype in ovarian cancer. Chin Med J 2011, 124:3133-3140.
56. Bingle L., Cross S.S., High A.S., et al. WFDC2 (HE4): a potential role in the innate immunity of the oral cavity and respiratory tract and the development of adenocarcinomas of the lung. Respir Res 2006, 10.1186/1465-9921-7-61.
57. Bingle L., Singleton V., Bingle C.D. The putative ovarian tumor marker gene HE4 (WFDC2), is expressed in normal tissues and undergoes complex alternative splicing to yield multiple protein isoforms. Oncogene 2002, 21:2768-2777.
58. Galgano M.T., Hampton G.M., Frierson H.F. Comprehensive analysis of HE4 expression in normal and malignant human tissues. Mod Pathol 2006, 19:847-853.
59. Wang K., Gan L., Jeffrey E., et al. Monitoring gene expression profile changes in ovarian carcinomas using cDNA microarray. Gene 1999, 229:101-108.
60. Schummer M., Ng W.V., Bumgarner R.E., et al. Comparative hybridization of an array of 21500 ovarian cDNAs for the discovery of genes overexpressed in ovarian carcinomas. Gene 1999, 238:375-385.
61. Hough C.D., Shermann-Baust C.A., Pizer E.S., et al. Large-scale serial analysis of gene expression reveals genes differentially expressed in ovarian cancer. Cancer Res 2000, 60:6281-6287.
62. Perou C.M., Sorlie T., Eisen M.B., et al. Molecular portraits of human breast tumors. Nature 2000, 406:747-752.
63. Ross D.T., Scherf U., Eisen M.B., et al. Systematic variation in gene expression patterns in human cancer cell lines. Nat Genet 2000, 24:227-235.
64. Bolstad N., Oijordsbakken M., Nustad K., Bjerner J. Human epididymis protein 4 reference limits and natural variations in a Nordic reference population. Tumor Biol 2008, 44:251-256.
65. Montagnana M., Danese E., Ruzzenente O., et al. The ROMA (Risk of Ovarian Malignancy Algorithm) for estimating the risk of epithelial ovarian cancer in women presenting with pelvic mass: is it really useful?. Clin Chem Lab Med 2011, 49:521-525.
66. Moore R.G., Jabre-Raughley M., Brown A.K., et al. Comparison of a novel multiple marker assay vs the Risk of Malignancy Index for the prediction of epithelial ovarian cancer in patients with a pelvic mass. Am J Obstet Gynecol 2010, 203:e1-e6.
67. Moore R.G., Miller M.C., Steinhoff M.M., et al. Serum HE4 levels are less frequently elevated than CA 125 in women with benign gynecological disorders. Am J Obstet Gynecol 2012, 206:351.e1-351.e8.
68. Wu L., Dai Z.Y., Qian Y.H., Shi Y., Liu F.J., Yang C. Diagnostic value of serum human epididymis protein 4 (HE4) in ovarian carcinoma. Int J Gynecol Cancer 2012, 22:1106-1112.
69. Wang J., Gao J., Yao H., Wu Z., Wang M., Qi J. Diagnostic accuracy of serum HE4, CA 125 and ROMA in patients with ovarian cancer: a meta analysis. Tumor Biol 2014, 35:6127-6138.
70. Lin J.Y., Qin J.B., Li X.Y., Dong P., Yin B.D. Diagnostic value of human epididymis protein 4 compared with mesothelin for ovarian cancer: a systematic review and meta-analysis. Asian Pac J Cancer Prev 2012, 13:5427-5432.
71. Lin J.Y., Qin J., Sangvatanakul V. Human epididymis protein 4 for differential diagnosis between benign gynaecologic disease and ovarian cancer: a systematic review and meta-analysis. Eur J Obstet Gynecol Reprod Biol 2012, 167:81-85.
72. Hellstrom I., Hellstrom K.E. SMRP and HE4 as biomarkers for ovarian carcinoma when used alone and in combination with CA 125 and/or each other. Adv Exp Med Biol 2008, 622:15-21.
73. Holomb K., Vucetic Z., Miller M.C., Knapp R. Human epididymis protein 4 offers superior specificity in the differentiation of benign and malignant adnexal masses in premenopausal women. Am J Obstet Gynecol 2011, 205. [358. e1-6].
74. Hallamaa M., Suvitie P., Huhtinen K., Matomäki J., Poutanen M., Perheentupa A. Serum HE4 concentration is not dependent on menstrual cycle or hormonal treatment among endometriosis patients and healthy premenopausal women. Gynecol Oncol 2012, 125:667-672.
75. Anastasi E., Granato T., Falzarano R., et al. The use of HE4, CA 125 and CA 72-4 biomarkers for differential diagnosis between ovarian endometrioma and epithelial ovarian cancer. J Ovarian Res 2013, 6:44.
76. Zheng H., Gao Y. Serum HE4 as a useful biomarker in discriminating ovarian cancer from benign disease. Int J Gynecol Cancer 2012, 22:1000-1005.
77. Huhinten K., Suvitie P., Hiissa J., et al. Serum HE4 concentration differentiates malignant tumours from ovarian endometriotic cysts. Br J Cancer 2009, 100:1315-1319.
78. Xu L., Cai J., Yang Q., et al. Prognostic significance of several biomarkers in epithelial ovarian cancer: a meta analysis of published studies. J Cancer Res Clin Oncol 2013, 139:1257-1277.
79. Steffensen K.D., Waldstrom M., Brandslund I., Petzold M., Jakobsen A. The prognostic and predictive value of combined HE4 and CA125 in ovarian cancer patients. Int J Gynecol Cancer 2012, 22:1474-1482.
80. Kong S.Y., Han M.H., Yoo H.J., et al. Serum HE4 level is an independent prognostic factor in epithelial ovarian cancer. Ann Surg Oncol 2012, 19:1707-1712.
81. Chen W.T., Gao X., Han X.D., Zheng H., Guo L., Lu R.Q. HE4 as a serum biomarker for ROMA prediction and prognosis of epithelial ovarian cancer. Asian Pac J Cancer Prev 2014, 15:101-105.
82. Hynninen J., Auranen A., Dean K., et al. Serum HE4 profile during primary chemotherapy of epithelial ovarian cancer. Int J Gynecol Cancer 2011, 21:1573-1578.
83. Braicu E.I., Fotopoulou C., VanGorp T., Richter R., Chekerov R., Hall C. Preoperative HE4 expression in plasma predicts surgical outcome in primary ovarian cancer patients. Results from the OVCAD study. Gynecol Oncol 2013, 128:245-251.
84. Chudecka-Głaz A., Rzepka-Górska I., Wojciechowska I. Human epididymal protein 4 (HE4) is a novel biomarker and promising prognostic factor in ovarian cancer patients. Eur J Gynaecol Oncol 2012, 33:382-390.
85. Chudecka-Głaz A.M., Cymbaluk-Płoska A.A., Menkiszak Jl, Sompolska-Rzechuła A.M., Tołoczko-Grabarek A.I., Rzepka-Górska I.A. Serum HE4, CA125, YKL-10, bcl-2, cathepsin-l and prediction optimal debulking surgery, response to chemotherapy in ovarian cancer. J Ovarian Res 2014, 7:62.
86. Angioli R., Plotti F., Capriglione S., et al. Can the preoperative HE4 level predict optimal cytoreduction in patients with advanced ovarian carcinoma?. Gynecol Oncol 2013, 128:579-583.
87. Anastasi E., Marchei G.G., Viggiani V., Gennarini G., Frati L., Reale M.G. HE4: a potential early biomarker for the recurrence of ovarian cancer. Tumor Biol 2010, 31:113-119.
88. Plotti F., Capriglione S., Terranova C., et al. Does HE4 have a role as biomarker in the recurrence of ovarian cancer. Tumor Biol 2012, 33:2117-2123.
89. Geurts S.M., de Veght F., van Altena A.M., et al. Considering early detection of relapsed ovarian cancer : a review of the literature. Int J Gynecol Cancer 2011, 21:837-845.
90. Park Y., Lee J.H., Hong D.J., Lee E.Y., Kim H.S. Diagnostic performance of HE4 and CA125 for the detection of ovarian cancer from patients with various gynecologic and non-gynecologic diseases. Clin Biochem 2011, 44:884-888.
91. Kim Y.M., Whang D.H., Park J., et al. Evaluation of accuracy of serum human epididymis protein 4 in combination with CA 125 for detecting ovarian cancer : a prospective case control study in Korean population. Clin Chem Lab Med 2011, 49:527-534.
92. Azzam A.Z., Hashad D.I., Kamel N. Evaluation of HE4 as an extra biomarker to CA 125 to improve detection of ovarian carcinoma: is it time for step forward. Arch Gynecol Obstet 2013, 288:167-172.
93. Andersen M.R., Goff B.A., Kimberly A.L., et al. Use of a symptom index, CA 125 and HE4 to predict ovarian cancer. Gynecol Oncol 2010, 116:378-383.
94. Yip P., Chen T.H., Seshaiah P., Stephen L., Michael -Ballard K.L., Mapes J.P., et al. Comprehensiveserum profiling for the discovery of epithelial ovarian cancer biomarkers. PLos ONE 2011, 6(12):e29533.
95. Li J., Chen H., Mariani A., et al. HE4 (WFDC2) promotes tumour growth in endometrial cancer cell lines. Int J Mol Sci 2013, 14:6026-6043.
96. Moore R.G., Brown A.K., Miller M.C., et al. The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass. Gynecol Oncol 2008, 108:402-408.
97. Su Z., Graybill W.S., Zhu Y. Detection and monitoring of ovarian cancer. Clin Chim Acta 2013, 415:341-345.
98. TM) Prod. No. 404-10US. Instructions for use. 2011-09.
99. ElecsysR® HE4 and CA 125 II and their use in the risk assessment of epithelial ovarian cancer by ROMA (Risk of Ovarian Malignancy). Roche multicentre evaluation study 2011.
100. Two strong pillars in the management of ovarian cancer ARCHITECT HE4+CA125 2014, Abbott Laboratories.
101. HE4 EIA Prod. No. 404-10. Instructions for use. 2014-04.
102. Chan K., Chen Ch., Nam J.H., et al. The use of HE4 in the prediction of ovarian cancer in Asian women with pelvic mass. Gynecol Oncol 2013, 128:239-244.
103. Ortiz-Munoz B., Aznar-Oroval E., Garcia A.G., et al. HE4, CA 125 and ROMA algorithm for differential diagnosis between benign gynaecological diseases and ovarian cancer. Tumor Biol 2014, 35:7249-7258.
104. Lenhardt M., Stieber P., Hertlein L., et al. The diagnostic accuracy of two epididymis protein 4 (HE4) testing system in combination with CA 125 in the differential diagnosis of ovarian masses. Clin Chem Lab Med 2011, 49:2081-2088.
105. Kalapotharakos G., Asciutto Ch., Henic B., Casslen B., Borgfeldt Ch. High preoperative blood levels of HE4 predicts poor prognosis in patients with ovarian cancer. J Ovarian Res 2012, 5:20.
106. Ruggieri G., Bandiera E., Zanotti L., et al. HE4 and epithelial ovarian cancer: comparison and clinical evaluation of two immunoassays and a combination algorithm. Clin Chim Acta 2011, 412:1447-1453.
107. Yang J., Sa M., Huang M., et al. The reference intervals for HE4, CA 125, and ROMA in healthy female with electrochemiluminescence immunoassay. Clin Biochem 2013, 46:1705-1708.
108. Van Gorp T., Cadron I., Despierre E., et al. HE4 and CA 125 as diagnostic test in ovarian cancer: prospective validation of the risk of ovarian malignancy algorithm. Br J Cancer 2011, 104:863-870.
109. Fritz-Rdzanek A., Grzybowski W., Beta J., Durczyński A., Jakimiuk A. HE4 protein and SMRP: potential novel biomarkers in ovarian cancer detection. Oncol Lett 2012, 4:385-389.
110. Kobayashi E., Ueda Y., Matsuzaki S., et al. Biomarkers for screening, diagnosis and monitoring ovarian cancer. Cancer Epidemiol Biomarkers Prev 2012, 21:1902-1912.
111. Kaijser J., Bourne T., Valentin L., et al. Improving strategies for diagnosisng ovarian cancer: a summary of the international ovarian tumor analysis (IOTA) studies. Ultrasound Obstet Gynecol 2013, 41:9-20.
112. Hakansson F., Hodgall E.V., Nedergaard L., et al. DANISH PELVIC MASS OVARIAN CANCER STUDY. Risk of malignancy index used as diagnostic tool in a tertiary centre for patients with pelvic mass. Acta Obstet Gynecol Scand 2012, 91:496-502.
113. Jacob F., Meier M., Caduff R., et al. No benefit from combining HE4 and CA 125 as ovarian tumor markers in a clinical setting. Gynecol Oncol 2011, 121:487-491.
114. Partheen K., Kristjansdottir B., Sundfeldt K. Evaluation of ovarian cancer biomarkers HE4 and CA-125 in women presenting with a suspicious cystic ovarian mass. J Gynecol Oncol 2011, 22:244-252.
115. Molina R., Escudero J.M., Auge J.M., et al. Her novel tumor marker for ovarian cancer: comparison with CA 125 and ROMA algorithm in patients with gynaecological diseases. Tumor Biol 2011, 32:1087-1095.
116. Sandri M.T., Bottari F., Franchi D., et al. Comparison of HE4, CA125 and ROMA algorithm in women with a pelvic mass: correlation with pathological outcome. Gynecol Oncol 2013, 128:233-238.
117. Karlsen M.A., Sandhu N., Hodgall C., et al. Evaluation of HE4, CA 125, risk of malignancy algorithm (ROMA) and risk of malignancy index (RMI) as diagnostic tools of epithelial ovarian cancer patients with pelvic mass. Gynecol Oncol 2012, 127:379-383.
118. Van Calster B., Timmerman D., Valentin L., et al. Triaging women with ovarian masses for surgery: observational diagnostic study to compare RCOG guidelines with an International Ovarian Tumour Analysis (IOTA) group protocol. BJOG 2012, 119:662-671.
119. Novotny Z., Presl J., Kucera R., et al. HE4 and ROMA index in Czech postmenopausal women. Anticancer Res 2012, 32:4137-4140.
120. Ledermann J.A., Raja F.A., Fotopoulou C., et al. Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow up. Ann Oncol 2012, 24(Supplement 6):vi24-vi32.
121. Rustin G.J., van der Burg M.E. A randomized trial in ovarian cancer (OC) of early treatment of relapse based on CA125 level alone versus delayed treatment based on conventional clinical indicators (MRC OV05/EORTC 55955 trials). J Clin Oncol 2009, 27(Suppl.):1. on behalf of MRC and EORTC collaborators, [abstr].
122. Granato T., Midulla C., Longo F., Calaprisca B., Frati L., Anastasi E. Role of HE4, CA 72.4 and CA 125 in monitorin ovarian cancer. Tumor Biol 2012, 33:1335-1339.
123. Anastasi E., Marchei G.G., Viggiani V., Gennarini G., Frati L., Reale M.G. HE4: a new potential early biomarker for the recurrence of ovarian cancer. Tumor Biol 2010, 31:113-119.